Agenda for Day 1 - Monday 9 November, 2026Monday, 9 November 2026

Powered by leading analyst intelligence and data-driven insights, this session offers a comprehensive exploration of the evolving therapeutic landscape. Dive into emerging trends, market dynamics, and investment opportunities across key therapeutic areas, and uncover how shifting R&D pipelines, regulatory changes, scientific breakthroughs, and technological advancements are transforming the biopharma industry. Gain a forward-looking perspective on the most promising therapeutic areas and high-growth investment opportunities, equipping you with the strategic insights needed to navigate 2026 and beyond.

Antibody-drug conjugates (ADCs) are transforming cancer treatment by delivering targeted therapy with precision, and as clinical data matures, they are attracting significant investment and partnership activity across the oncology landscape. This session examines the latest evidence on efficacy and safety, explores what the data reveals about how ADCs are reshaping treatment strategies across tumour types, and discusses which platforms and targets are capturing attention from investors and partners. With deal flow accelerating and new opportunities emerging, the session provides strategic considerations for evaluating partnerships and investments in this high-value oncology segment.

Oncology remains the largest and most competitive area of biotech innovation, but the path to success is becoming increasingly complex. Emerging modalities such as radioligand therapies, next-generation immunotherapies, cell therapies and precision-targeted approaches are generating significant excitement, yet investors and pharmaceutical companies are becoming more selective in how they evaluate risk, differentiation and commercial potential.

This panel brings together biotech innovators, pharma leaders and investors to discuss which oncology platforms are attracting the strongest scientific, partnering and investment interest, what makes a company stand out in a crowded landscape, and how capital, partnerships and clinical strategy can accelerate value creation. The discussion will explore where the next major opportunities in oncology may emerge and what will separate future winners from the rest of the field.

• Are radioligands becoming the next oncology platform?

• Can immunotherapy continue to generate venture-scale returns?

• Is precision medicine becoming too fragmented?

What separates fundable oncology companies from unfundable.

Cell and gene therapies are redefining treatment possibilities across multiple diseases, and despite market challenges, they continue to command substantial investment and strategic interest. This session provides essential insights into the current landscape, highlights key developments across platforms and indications, and examines what recent clinical and commercial data reveal about the sector's trajectory. With deal dynamics evolving and new modalities emerging, the session explores funding trends, partnership strategies, and what key stakeholders need to know to navigate opportunities in this transformative field.